UBS Group’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,074,924
| Closed | -$237M | – | 10554 |
|
|
2025
Q4 | $237M | Buy |
1,074,924
+601,370
| +127% | +$97.2M | 0.04% | 494 |
|
|
2025
Q3 | $45.3M | Buy |
473,554
+295,644
| +166% | +$18.9M | 0.01% | 1735 |
|
|
2025
Q2 | $8.67M | Buy |
177,910
+111,097
| +166% | +$2.67M | ﹤0.01% | 3233 |
|
|
2025
Q1 | $1.44M | Buy |
66,813
+19,942
| +43% | +$443K | ﹤0.01% | 4983 |
|
|
2024
Q4 | $1.26M | Buy |
46,871
+40,994
| +698% | +$666K | ﹤0.01% | 5134 |
|
|
2024
Q3 | $63.2K | Buy |
5,877
+4,410
| +301% | +$53K | ﹤0.01% | 6668 |
|
|
2024
Q2 | $17.5K | Buy |
1,467
+1,232
| +524% | +$16.9K | ﹤0.01% | 7389 |
|
|
2024
Q1 | $4.32K | Buy |
+235
| New | +$3.37K | ﹤0.01% | 7637 |
|
|
2022
Q3 | – | Sell |
-1
| Closed | – | – | 10381 |
|
|
2022
Q2 | $0 | Sell |
1
-85
| -99% | -$1.05K | ﹤0.01% | 10363 |
|
|
2022
Q1 | $1K | Buy |
86
+85
| +8,500% | +$1.44K | ﹤0.01% | 9848 |
|
|
2021
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 10280 |
|
|
2021
Q3 | $0 | Sell |
1
-299
| -100% | -$11.4K | ﹤0.01% | 9577 |
|
|
2021
Q2 | $12K | Sell |
300
-856
| -74% | -$36.2K | ﹤0.01% | 7871 |
|
|
2021
Q1 | $62K | Sell |
1,156
-96
| -8% | -$4.74K | ﹤0.01% | 6335 |
|
|
2020
Q4 | $50K | Sell |
1,252
-6,460
| -84% | -$321K | ﹤0.01% | 6180 |
|
|
2020
Q3 | $440K | Buy |
7,712
+658
| +9% | +$46.5K | ﹤0.01% | 4294 |
|
|
2020
Q2 | $520K | Buy |
7,054
+5,312
| +305% | +$344K | ﹤0.01% | 4101 |
|
|
2020
Q1 | $87K | Buy |
1,742
+1,610
| +1,220% | +$96.5K | ﹤0.01% | 5409 |
|
|
2019
Q4 | $10K | Sell |
132
-321
| -71% | -$14.7K | ﹤0.01% | 7276 |
|
|
2019
Q3 | $18K | Buy |
453
+17
| +4% | +$571 | ﹤0.01% | 6794 |
|
|
2019
Q2 | $14K | Sell |
436
-108
| -20% | -$4.49K | ﹤0.01% | 6836 |
|
|
2019
Q1 | $29K | Buy |
544
+72
| +15% | +$3.95K | ﹤0.01% | 5968 |
|
|
2018
Q4 | $22K | Buy |
472
+240
| +103% | +$17.1K | ﹤0.01% | 6695 |
|
|
2018
Q3 | $20K | Sell |
232
-130
| -36% | -$11.5K | ﹤0.01% | 6787 |
|
|
2018
Q2 | $38K | Buy |
362
+168
| +87% | +$15.9K | ﹤0.01% | 6207 |
|
|
2018
Q1 | $15K | Buy |
194
+124
| +177% | +$16.9K | ﹤0.01% | 6609 |
|
|
2017
Q4 | $10K | Buy |
+70
| New | +$10.6K | ﹤0.01% | 7004 |
|
|
2017
Q3 | – | Sell |
-7
| Closed | -$1K | – | 7735 |
|
|
2017
Q2 | $1K | Sell |
7
-59
| -89% | -$8.15K | ﹤0.01% | 7478 |
|
|
2017
Q1 | $10K | Sell |
66
-290
| -81% | -$50.9K | ﹤0.01% | 6599 |
|
|
2016
Q4 | $74K | Buy |
356
+223
| +168% | +$46.3K | ﹤0.01% | 5515 |
|
|
2016
Q3 | $31K | Buy |
+133
| New | +$30.7K | ﹤0.01% | 5890 |
|
|
2015
Q4 | – | Sell |
-49
| Closed | -$12K | – | 8352 |
|
|
2015
Q3 | $12K | Buy |
49
+48
| +4,800% | +$13.7K | ﹤0.01% | 7138 |
|
|
2015
Q2 | $0 | Buy |
+1
| New | +$308 | ﹤0.01% | 8508 |
|
UBS Group's CDTX Position: Q1 2026 in Review
UBS Group sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 1,074,924 shares — an estimated $237M sold.
UBS Group first reported a position in CDTX in Q2 2015 and held it in 33 quarters. The position peaked at $237M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- UBS Group reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 1,074,924 Cidara Therapeutics shares in Q1 2026, an estimated $237M.
- UBS Group first reported a position in Cidara Therapeutics in Q2 2015 and held it in 33 quarters.
- UBS Group's Cidara Therapeutics position peaked at $237M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.